FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      
           
This page is updated frequently with new Antibodies-related patent applications. Subscribe to the Antibodies RSS feed to automatically get the update: related Antibodies RSS feeds. RSS updates for this page: Antibodies RSS RSS


Date/App# patent app List of recent Antibodies-related patents
09/11/14
20140259212
 Process for the production of fine chemicals patent thumbnailProcess for the production of fine chemicals
The present invention relates to a process for the production of a fine chemical in a non-human organism, like a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, expression cassettes, vectors, antibodies, host cells, plant tissue, propagation material, harvested material, plants, microorganisms as well as agricultural compositions and to their use..
09/11/14
20140256915
 Velocity factor patent thumbnailVelocity factor
The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e.
09/11/14
20140256583
 Detection of human endogenous retrovirus expression in cancer and normal cells patent thumbnailDetection of human endogenous retrovirus expression in cancer and normal cells
The invention relates to human endogenous retrovirus env (herv-wl) polypeptides, nucleotide sequences, herv-wl antibodies, methods to detect cancer, and methods to determine the effectiveness of the treatment of cancer.. .
09/11/14
20140256579
 Protein arrays patent thumbnailProtein arrays
Protein arrays are provided comprising single domain antibodies obtainable from camelidae which are capable of detecting even minor changes in the expression of proteins in cell and tissue extracts and having an optimal signal to noise ratio by removing non-informative abundant proteins from said cell or tissue extracts.. .
09/11/14
20140256041
 Methods of blocking cancer stem cell growth patent thumbnailMethods of blocking cancer stem cell growth
Disclosed herein are antibodies against gpr49 and uses of such antibodies. The antibodies can be monoclonal, humanized, or fully human antibodies against gpr49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of blocking cancer stem cell growth with such antibodies..
09/11/14
20140255995
 High affinity antibodies to human il-6 receptor patent thumbnailHigh affinity antibodies to human il-6 receptor
A human antibody or an antigen-binding fragment which binds human il-6 receptor (hil-6r) with a kd of about 500 pm or less and blocks il-6 activity with an ic50 of 200 pm or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hil-6r with an affinity at least 2-fold higher relative to its binding monkey il-6r..
09/11/14
20140255957
 Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis patent thumbnailAntigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
The present invention provides citrullinated 14-3-3η peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.. .
09/11/14
20140255956
 Diagnosis of myocardial autoimmunity in heart disease patent thumbnailDiagnosis of myocardial autoimmunity in heart disease
Provided herein are, inter alia, methods of diagnosing myocardial autoimmunity in subjects by detecting the presence of autoantibodies to cardiac antigens in the subjects.. .
09/11/14
20140255955
 Method of diagnosing sjogren's disease patent thumbnailMethod of diagnosing sjogren's disease
Provided are methods and compositions for determining whether an individual has sjögren's disease (sd). The method entails determining in a biological sample from the individual the presence of antibodies directed to salivary gland protein 1 (sp-1), parotid secretory protein (psp), carbonic anhydrase 6 (ca6), or determining a combination of the antibodies.
09/11/14
20140255951
 Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor patent thumbnailAntibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
The present disclosure provides lysyl oxidase-like-2 (loxl2) polypeptide binding agents, including, for example, antibodies that specifically bind a loxl2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided..
09/11/14
20140255429
Methods of treating autoimmune diseases with dll4 antagonists
The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory t cell (treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of dll4 antagonists that block dll4-notch signal pathways, thereby increasing the number of treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (ms), diabetes, and the like.
09/11/14
20140255423
Isolation and purification of antibodies using protein a affinity chromatography
Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise ph viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably protein a affinity, ion exchange chromatography, and hydrophobic chromatography.
09/11/14
20140255422
Antibodies that bind to il-23
The present invention provides an antibody that binds to the p19 subunit of human il-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome.
09/11/14
20140255420
Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, β-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-cd3 antibody.
09/11/14
20140255419
Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
The present invention provides antibodies that bind to the human glucagon receptor, designated gcgr and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human gcgr.
09/11/14
20140255414
Diagnostic antibody assay
Novel diagnostic assays for the diagnosis of amyloidosis, in particular alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided..
09/11/14
20140255412
Pharmaceutical composition of an antigenic tau peptide reconstituted in a liposome and related antibodies and cell lines
The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to pharmaceutical compositions comprising an antigenic peptide, particularly an antigenic phopho-peptide mimicking a major pathological phosphor-epitope of protein tau, for the therapeutic and diagnostic use in the treatment of tauopathies including alzheimer's disease..
09/11/14
20140255411
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
09/11/14
20140255408
Bispecific egfr/c-met antibodies
Bispecific egfr/c-met antibodies and methods of making and using the molecules.. .
09/11/14
20140255406
Anti-tnf-anti-il-17 bispecific antibodies
Bispecific antibodies are provided that specifically bind both tumor necrosis factor alpha (tnfα) and interleukin-17 (il-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including rheumatoid arthritis (ra), psoriatic arthritis (psa), and ankylosing spondylitis (as)..
09/11/14
20140255399
Separation method for fucosylated antibodies
The present invention relates to a method for the separation of antibodies, specifically antibodies having different degrees of fucosylation. The method is based on binding affinity of antibodies to fc receptors.
09/11/14
20140255396
Multiple-variable dose regimen for treating tnfalpha-related disorders
Multiple-variable dose methods for treating tnfα-related disorders, including crohn's disease and psoriasis, comprising administering tnfα inhibitors, including tnfα antibodies, are described. Multiple-variable dose methods include administration of a tnf-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the tnf-inhibitor is administered in a higher dosage during the induction phase..
09/11/14
20140255389
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
09/11/14
20140255346
Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis
Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (pbmcs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to cns antigens associated with multiple sclerosis (ms). These cns antigens include, but are not limited to whole brain lysate and the myelin antigens myelin basic protein (mbp), myelin oligodendrocyte glycoprotein (mog), mog peptides (mogps), proteolipid protein (plp), and plp peptides (plpps).
09/11/14
20140255343
Dna vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine
The object of the invention is a dna vaccine, method of inducing the immune response, antibodies specifically recognising the haemagglutinin h5 of an influenza virus and application of the dna vaccine. According to the invention, one or two-fold immunisation of hens with dna vaccine containing a cdna encoding the modified h5 haemagglutinin ha protein, i.e.
09/11/14
20140255313
Compositions and methods for detecting protease activity in biological systems
The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.. .
09/11/14
20140255304
Tdp-43 specific binding molecules
Provided are novel tdp-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these tdp-43 specific binding molecules.
09/11/14
20140255302
Antibodies against tl1a and uses thereof
The disclosure provides tnf-like ligand 1a (tl1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to tl1a and inhibits interaction of tl1a and death receptor 3 (dr3) and which does not inhibit the interaction of tl1a and decoy receptor 3 (dcr3). The disclosure also provides uses of the tl1a-binding proteins..
09/04/14
20140249298
Anti-human equilibrative nucleoside transporter 1 (hent1) antibodies adn methods of use thereof
This invention provides monoclonal antibodies that recognize hent1. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in disorders associated with aberrant hent1 expression and/or activity..
09/04/14
20140249297
Antibodies with modified isoelectric points
The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. Increased serum half-life in vivo..
09/04/14
20140249296
Using sortases to install click chemistry handles for protein ligation
Methods and reagents for the installation of click chemistry handles on target proteins are provided, as well as modified proteins comprising click chemistry handles. Further, chimeric proteins, for example, bi-specific antibodies, that comprise two proteins conjugated via click chemistry, as well as methods for their generation and use are disclosed herein..
09/04/14
20140249048
Novel prostate kallikrein allergen
Methods for in vitro diagnosis of type i allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type i allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of seq id no: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of seq id no: 1; and detecting the presence, in the sample, of ige antibodies specifically binding to the variant or fragment. The presence of such ige antibodies specifically binding to the variant or fragment is indicative of a type i allergy in the patient..
09/04/14
20140249044
Cell-based methods for coupling protein interactions and binding molecule selection and diversification
The invention relates to cell-based methods for diversifying, expressing and selecting binding molecules, e.g., antibodies, and target molecules to which they bind, all of which are expressed in the same cell. The target molecule can be a member of a ligand binding pair comprising a cell-surface expressed ligand binding receptor molecule and its cognate ligand, which interact within the cell.
09/04/14
20140249042
Detection of bioagents using a shear horizontal surface acoustic wave biosensor
Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers).
09/04/14
20140248666
Epitopes
Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.. .
09/04/14
20140248665
Novel intron sequences
The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns..
09/04/14
20140248664
Readily isolated bispecific antibodies with native immunoglobulin format
A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the ch3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the ch3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as protein a, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for protein a.. .
09/04/14
20140248661
Zcytor19 polynucleotides, polypeptides, antibodies and methods of use
Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class ii cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo.
09/04/14
20140248660
Heterologous intron within a signal peptide
The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns..
09/04/14
20140248638
Oxmif as a diagnostic marker
The present invention pertains to the recognition that a specific oxmif form of mif is useful as a diagnostic marker in (mif-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies..
09/04/14
20140248303
Synthetic streptococcus pneumoniae vaccine
Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the r21 or r22 domain of cbpa or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation.
09/04/14
20140248301
Method of inducing the production of protective anti-hiv-1 antibodies
The present invention relates, in general, to an immunogen for hiv vaccination and, in particular, to a method of inducing the production of protective anti-hiv antibodies by targeting b cell germline and clone intermediates using a combination of hiv envelope and non-hiv immunogens. The invention also relates to compositions suitable for use in such a method..
09/04/14
20140248297
Predictors of response to immunotherapy
The invention is directed to a method to predict individuals who are likely to respond to immunotherapy by detecting enhanced levels of antibodies in the plasma or serum wherein the antibodies are characteristic of the response or non-response of pretested populations of subjects.. .
09/04/14
20140248295
Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
Disclosed herein are glycan-modified anti-cd4 monoclonal antibodies with n-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for hiv prevention and therapy are also disclosed..
09/04/14
20140248286
Anti-hemagglutinin antibodies and methods of use
The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.. .
09/04/14
20140248283
Monoclonal antibodies against her2 antigens, and uses therefor
The present invention provides and includes monoclonal antibodies (mabs) preferentially selective for her2 antigens, hybridoma lines that secrete these her2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect her2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of her2.
09/04/14
20140248282
Novel anti-ddr1 antibody having anti-tumor activity
As a result of producing anti-ddr1 antibodies and conducting extensive studies on the antitumor activity thereof, antibodies that bind to the stalk domain in the amino acid sequence of human ddr1 were found to have a potent activity even when used alone compared to antibodies that bind to other domains. It was also found that the antibodies have one or more activities selected from the group consisting of: (i) an activity to suppress cell proliferation, (ii) an activity to inhibit cell migration, (iii) an activity to inhibit phosphorylation of ddr1 in cells, (iv) an activity to be taken up into cells, (v) an activity to decrease the expression level of ddr1 in cells, and (vi) an activity to decrease the expression level of tgf-β in cells..
09/04/14
20140248280
Anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
Provided are methods and compositions for clinical treatment of advanced gynecological cancers using anti-erbb3 antibodies combined with paclitaxel.. .
09/04/14
20140248277
Multiple-variable dose regimen for treating tnfalpha-related disorders
Multiple-variable dose methods for treating tnfα-related disorders, including crohn's disease and psoriasis, comprising administering tnfα inhibitors, including tnfα antibodies, are described. Multiple-variable dose methods include administration of a tnf-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the tnf-inhibitor is administered in a higher dosage during the induction phase..
09/04/14
20140248276
Multiple-variable dose regimen for treating tnfalpha-related disorders
Multiple-variable dose methods for treating tnfα-related disorders, including crohn's disease and psoriasis, comprising administering tnfα inhibitors, including tnfα antibodies, are described. Multiple-variable dose methods include administration of a tnf-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the tnf-inhibitor is administered in a higher dosage during the induction phase..
09/04/14
20140248275
Multiple-variable dose regimen for treating tnfalpha-related disorders
Multiple-variable dose methods for treating tnfα-related disorders, including crohn's disease and psoriasis, comprising administering tnfα inhibitors, including tnfα antibodies, are described. Multiple-variable dose methods include administration of a tnf-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the tnf-inhibitor is administered in a higher dosage during the induction phase..
09/04/14
20140248274
Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilisate as well as the use of a sugar or amino sugar, an amino acid and a surfactant as stabilizers for therapeutic or diagnostic agents containing antibodies..
09/04/14
20140248272
Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in treponema spp.
09/04/14
20140248271
Novel human genes relating to respiratory diseases and obesity
This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein..
09/04/14
20140248267
Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same
The present invention relates to antibodies that bind cd33. More particularly, the invention relates to anti-cd33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications.
09/04/14
20140248265
Therapeutic antibodies binding il 12rbeta1
The present invention relates to antibodies that specifically bind to il12rβ1, the non-signal transducing chain of the heterodimeric il12 receptor (together with il12rβ2 chain) as well as il23 receptor (together with il23rα chain). The invention more specifically relates to specific antibodies that are il12 and il23 receptor antagonists capable of inhibiting il12/il18 induced ifny production of t cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting ifny production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders..
08/28/14
20140245491
Axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230 and axmi231 delta-endotoxin genes and methods for their use
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
08/28/14
20140243508
Method for the purification of antibodies
A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin.
08/28/14
20140243507
Method of screening antibodies with high antigen selectivity
Provided is a method of screening a target-specific antibody for an antigen that undergoes structural change in a particular physiological condition.. .
08/28/14
20140243505
Bispecific antibody
Provided are bispecific antibodies comprised of a single-chain unit having specificity to an immune cell and a monovalent unit having specificity to a tumor cell or a microorganism. The single-chain unit includes a single-chain variable fragment (scfv) fused to an fc fragment and the monovalent unit includes a light chain and heavy chain pair.
08/28/14
20140243504
Antibodies comprising chimeric constant domains
Antibodies, antigen-binding proteins and fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric fc-containing antibodies, antigen-binding proteins and fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric fc-containing proteins are provided..
08/28/14
20140243432
Peptide biomarkers of cardiovascular disease
The presently-disclosed subject matter provides methods for diagnosing a cardiovascular disease in a subject by determining an amount of one or more peptide biomarkers disclosed herein in a biological sample from the subject. The presently-disclosed subject matter further provides methods for determining treatment efficacy and/or progression of a cardiovascular disease in a subject by measuring amounts of one or more of the biomarkers in a biological sample from the subject.
08/28/14
20140243265
Antibodies to modified human igf-1/e peptides
High-specificity antibodies can distinguish between modified (e.g, higf-1/ea 3mut) and endogenous wild-type human igf-1 proteins. These antibodies have little or no cross-reactivity with higf-1 or higf-2.
08/28/14
20140243228
High-throughput system and method for identifying antibodies having specific antigen binding activities
System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple dna libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently.
08/28/14
20140242727
Method for diagnosing alzheimer's disease (ad)
Disclosed is a method for diagnosing alzheimer's disease (ad) wherein aβ-specific antibodies in a biological sample of a person that is suspected of having ad are detected comprising the following steps: —contacting the sample with aβ-aggregates or with particles having aβ-aggregate like surfaces and allowing the aβ-specific antibodies to bind to the aβ-aggregates, and —detecting the aβ-specific antibodies bound to the aβ-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (facs); and wherein the amount of aβ-specific antibodies detected is compared with the amount in a sample of known ad status.. .
08/28/14
20140242723
Methods for detecting symmetrical dimethylarginine
Method of detecting symmetrical dimethyl arginine (sdma) in biological samples. Sdma analogs for generating anti-sdma antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine.
08/28/14
20140242637
Artificial introns
The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences..
08/28/14
20140242619
Equine parasite detection
The present invention provides a method of diagnosing a cyathostomin infection, said method comprising the step of identifying a level of anti-cyathostomin larval antigen antibodies in a sample, wherein a level of anti-cyathostomin larval antigen antibodies is indicative of a cyathostomin infection.. .
08/28/14
20140242618
Ritalinic acid immunoassay
The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies..
08/28/14
20140242617
Immunoassay for detecting kratom, its constituents and their use
The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites..
08/28/14
20140242597
Predicting tumor response to anti-erbb3 antibodies
A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an erbb3 inhibitor, e.g, an anti-erbb3 antibody, is disclosed. The method is based on measurement of nrg1 expression at the rna level, or at the protein level, in a tissue sample from the tumor..
08/28/14
20140242591
Method of diagnosing and preventing pneumococcal diseases using pneumococcal neuraminidases
A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: nana, nanb, and nanc of s.
08/28/14
20140242100
Methods and compositions for the generation and use of conformation-specific antibodies
The present invention features methods and compositions for the generation of conformation-specific antibodies.. .
08/28/14
20140242095
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
The invention relates to modulating the sirpα—cd47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided sirpα antibodies and antibody fragments, preferably used for treating hematological cancer..
08/28/14
20140242090
Methods for the treatment of il-1beta related conditions
Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-il-1β binding molecules (e.g., il-1β binding antibodies or binding fragment thereof).. .
08/28/14
20140242086
Polynucleotides encoding signal peptide-containing molecules
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
08/28/14
20140242083
Anti-mcsp antibodies
The invention provides anti-mcsp antibodies and methods of using the same.. .
08/28/14
20140242075
Antibody variants and uses thereof
Described herein are polypeptides and related antibodies comprising a variant fc domain. The variant fc domain provide for stabilized fc:fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as cdc-response..
08/28/14
20140242072
Anti-icam-1 antibodies to treat multiple-myeloma related disorders
The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for icam-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for icam-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods for the administration of such antibodies, fragments, variants, fusion and derivatives thereof..
08/28/14
20140242071
M-csf specific monoclonal antibody and uses thereof
M-csf-specific rx1-based or rx-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.. .
08/28/14
20140242070
Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulates fzd2. The antibody may specifically bind fzd2, and may promote internalization of the fzd2 receptor by the cancer cells and/or prevent ligand binding to fzd2.
08/28/14
20140242068
Jaml specific binding agents, antibodies, and uses related thereto
Disclosed are specific binding agents such as antibodies and chimera that bind to jam-like protein. Also disclosed are heavy chain fragments, light chain fragments, and cdrs of the antibodies, as well as methods related thereto..


Popular terms: [SEARCH]

Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.411

4095

2 - 1 - 88